Anaptysbio (ANAB) Operating Margin (2016 - 2026)
Anaptysbio's (ANAB) quarterly Operating Margin came in at 135.53% in Q1 2026, down 3637.0% YoY from 3.83% in Q1 2025, and down 251.94% on a QoQ basis from 89.2% in Q4 2025.
Anaptysbio (ANAB) Operating Margin (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Operating Margin data on file, last reported at 135.53% in Q1 2026.
- Quarterly Operating Margin fell 3637.0% year-over-year to 135.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.61% (up 15097.0% YoY) and the FY2025 annual result came in at 20.42%, up 14635.0% from the prior year.
- Operating Margin fell to 135.53% in Q1 2026, from 89.2% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 89.2% in Q4 2025 to a low of 3273.09% in Q1 2022.
- A 5-year average of 923.92% and a median of 467.91% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin plunged 308948 bps — and 2024, when it jumped 264367 bps.
- Tracing ANAB's Operating Margin over 5 years: stood at 519.46% in 2022, then grew by 10 bps to 467.91% in 2023, then surged by 92 bps to 38.68% in 2024, then surged by 331 bps to 89.2% in 2025, then tumbled by 252 bps to 135.53% in 2026.
- The last three Operating Margin figures came in at 135.53% (Q1 2026), 89.2% (Q4 2025), and 69.41% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -135.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135.53% |
| Dec 31, 2025 | 89.20% |
| Sep 30, 2025 | 69.41% |
| Jun 30, 2025 | -117.55% |
| Mar 31, 2025 | -99.16% |
| Dec 31, 2024 | -38.68% |
| Sep 30, 2024 | -151.71% |
| Jun 30, 2024 | -367.52% |
| Mar 31, 2024 | -587.84% |
| Dec 31, 2023 | -467.91% |
| Sep 30, 2023 | -1,137.19% |
| Jun 30, 2023 | -1,160.20% |
| Mar 31, 2023 | -3,231.51% |
| Dec 31, 2022 | -519.46% |
| Sep 30, 2022 | -2,291.80% |
| Jun 30, 2022 | -2,286.10% |
| Mar 31, 2022 | -3,273.09% |
| Dec 31, 2021 | -3,081.80% |
| Sep 30, 2021 | -33.82% |
| Jun 30, 2021 | -2.67% |